Are mood stabilizers beneficial in the treatment of schizophrenia?;Har stemningsstabiliserende legemidler noen plass i behandlingen av schizofreni?

Tidsskrift for den Norske Laegeforening

Volumn 125, Issue 13-14, 2005, Pages 1809-1812

  Berle, Jan Øystein ^a,b   Spigset, Olav ^c  

^a Haukeland Universitetssjukehus ^*  (Norway)

^b Regionsenter for Barn og Unges Psykiske Helse   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLOZAPINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE; ZUCLOPENTHIXOL;

CLINICAL TRIAL; DRUG INDICATION; HUMAN; MONOTHERAPY; MOOD DISORDER; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; CARBAMAZEPINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM; SCHIZOPHRENIA; VALPROIC ACID;

EID: 21844458447     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Peuskens J. The evolving definition of treatment resistance. J Clin Psychiatry 1999; 60 (suppl 12): 4-8.
2. Lapensee MA. A review of schizoaffective disorder: II. Somatic treatment. Can J Psychiatry 1992; 37: 347-9.
3. Keck PE, McElroy SL, Strakowski SM. New developments in the pharmacologic treatment of schizoaffective disorder. J Clin Psychiatry 1996; 57 (suppl 9): 41-8.
4. Suppes T, Webb A, Paul B et al. Clinical outcome in a randomized 1 year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156: 1164-9.
5. Weiden PJ, Casey DE. Polypharmacy: Combining antipsychotic medications in the treatment of schizophrenia. Journal of Practical Psychiatry and Behavioral Health 1999; 6: 229-33.
6. Clark RE, Bartels SJ, Mellman TA et al. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002; 28: 75-84.
7. Peacock L, Gerlach J. Clozapine treatment in Denmark: concomitant psychotrophic medication and hematologic monitoring in a system with liberal usage practice. J Clin Psychiatry 1994; 55: 44-9.
8. Citrome L, Levine J, Allingham B. Changes in the use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv 2000; 51: 634-8.
9. Citrome L. Schizophrenia and valproate. Psychopharmacol Bull 2003; 37 (suppl 2): 74-88.
10. Buckley P, Miller A, Olsen J et al. When symptoms persist: clozapine augmentation strategies. Schizophr Bull 2001; 27: 615-28.
11. Agranoff BW, Fischer SK. Inositol, lithium, and the brain. Psychopharmacol Bull 2001; 35: 5-18.
12. Meltzer HY. The role of serotonin in antispychotic drug action. Neuropsychopharmacology 1999; 21 (suppl 2): 106-15S.
13. Gould RJ, Murphy KMM, Reynolds IJ et al. Antischizophrenic drug of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc Natl Acad Sci USA 1983; 80: 5122-5.
14. Feinberg SS, Kay SR, Elijovich LR et al. Pimozide treatment of the negative schizophrenic syndrome: open trial. J Clin Psychiatry 1988; 49: 235-8.
15. Wassef A, Baker J, Kochan LD. GABA and schizophrenia: a review of basic science and clinical studies. J Clin Psychopharmacol 2003; 23: 601-40.
16. Goff DC, Coyle DC. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158: 1367-77.
17. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia revisited: a systemic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 2004; 65: 177-86.
18. American Psychiatric Association. Practice guidelines for the treatment of psychiatric disorders. Washington DC: American Psychiatric Press, 2002: 390-4.
19. McElroy SL, Keck PE, Pope HG jr. Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987; 7: 16-24.
20. Small JG, Kellams JJ, Milstein V et al. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 1975; 132: 1315-7.
21. Zemlan FP, Hirschowitz J, Sautter FJ et al. Impact of lithium therapy on core psychotic symptoms of schizophrenia. Br J Psychiatry 1984; 144: 64-9.
22. Atre-Vaidya N, Taylor MA. Effectiveness of lithium in schizophrenia: do we really have an answer? J Clin Psychiatry 1989; 50: 170-2.
23. Lerner Y, Mintzer Y, Schestatzky M. Lithium combined with haloperidol in schizophrenia patients. Br J Psychiatry 1988; 153: 359-62.
24. Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: Choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991; 17: 217-45.
25. Schulz SC, Kahn EM, Baker RW et al. Lithium and carbamazepine augmentation in treatment-refractory schizophrenia, I: Angrist B, Schulz SD, red. The neuroleptic-nonresponsive patient: characterization and treatment. Washington DC: American Psychiatric Press, 1990: 109-36.
26. Hogarty GE, McEvoy JP, Ulrich RF et al. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry 1995; 52: 29-41.
27. Lee SH, Yang YY. Reversible neurotoxicity induced by a combination of clozapine and lithium: A case report. Zhonghua Yi Xue Za Zhi (Taipei) 1999; 62: 184-7.
28. Garcia G, Crismon ML, Dorson PG. Seizures in two patients after the addition of lithium to a clozapine regimen. J Clin Psychopharmacol 1994; 14: 426-8.
29. Shopsin B, Kim SS, Gershon S. A controlled study of lithium vs. chlorpromazine in acute schizophrenics. Br J Psychiatry 1971; 119: 435-40.
30. Wilson WH. Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind placebo controlled, parallel design clinical trial. Psychopharmacology 1993; 111: 359-66.
31. Leucht S, McGrath J, White P et al. Carbamazepine augmentation for schizophrenia: how good is the evidence? J Clin Psychiatry 2002; 63: 218-24.
32. Leucht S, McGrath J, White P, Kissling W. Carbamazepine for schizophrenia and schizoaffective psychoses. Cochrane Database Syst Rev 2002: CD001258.
33. Luchins D. Carbamazepine in violent non-epileptic schizophrenics. Psychopharmacol Bull 1987; 20: 569-71.
34. Simhandl C, Meszaros K, Denk E et al. Adjunctive carbamazepine or lithium carbonate in the treatment of schizophrenia and schizoaffective psychoses: a review. J Psychiatry Neurosci 1992; 17: 1-14.
35. Johns CA, Thompson JW. Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy. Schizophr Bull 1995; 21: 607-19.
36. Okuma T, Yamashita I, Takahashi R et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand 1989; 80: 250-9.
37. Stockley IH. Drug interactions. 6. utg. London: The Pharmaceutical Press, 2002.
38. Hesslinger B, Klose P, Normann C et al. Zur adjuvanten Behandlung schizophener Störungen mit Carbamazepin. Fortschr Neurol Psychiatr 1998; 66: 145-50.
39. Junghan U, Albers M, Woggon B. Increased risk of hematological side-effects in patients treated with clozapine and carbamazepine? Pharmacopsychiatry 1993; 26: 262.
40. Gerson S, Arce C, Meltzer H. N-desmethylclozapine: a clozapine-metabolite that suppresses haematopoiesis. Br J Haematol 1994; 86: 551-61.
41. Casey DE, Daniel DG, Wassef AA et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003; 28: 182-92.
42. Citrome L, Casey DE, Daniel DG et al. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatr Serv 2004; 55: 290-4.
43. Dose M, Hellweg R, Yassouridis A et al. Combined treatment of schizophrenic psychoses with haloperiodol and valproate. Pharmacopsychiatry 1998; 31: 122-5.
44. Linnoila M, Viukari M, Kietala O. Effects of sodium valproate on tardive dyskinesia. Br J Psychiatry 1976; 129: 114-9.
45. Wassef AA, Hafiz NG, Hampton D et al. Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. J Clin Psychopharmacol 2001; 21: 21-6.
46. Ko GN, Korpi ER, Freed WJ et al. Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenic patients. Biol Psychiatry 1985; 20: 209-15.
47. Basan A, Leucht S. Valproate for schizophrenia. Cochrane Database Syst Rev 2004: CD004028.
48. Dursun SM, McIntosh D, Millikeu H. Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch Gen Psychiatry 1999; 56: 950.
49. Tiihonen J, Hallikainen T, Ryynänen OP et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 2003; 54: 1241-8.
50. Lingjasrde O. Behandling av schizofreni og beslektede psykoser. I: Psykofarmaka. Kristiansand: Høyskoleforlaget, 2001: 462-4
51. Buchanan RW, Kreyenbuhl J, Zito JM et al. Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. Am J Psychiatry 2002; 159: 1035-43.
52. Hosak L, Libiger J. Antiepileptic drugs in schizophrenia: a review. Eur Psychiatry 2002; 17: 371-8.
53. Rygnestad T. Bruk av legemidler utenfor godkjent indikasjon. Tidsskr Nor Lasgeforen 1998; 118: 932-3.
54. Simhandl C, Meszaros K, Denk E et al. Adjunctive carbamazepine or lithium carbonate in the treatment of schizophrenia and schizoaffective psychoses: a review. J Psychiatry Neurosci 1992; 17: 1-14.
55. Schulz SC, Thompsom PA, Jacobs M et al. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients J Clin Psychiatry 1999; 60: 366-72.
56. Terao T, Oga T, Nozaki S et al. Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, doublie-blind, placebo-controlled, cross-over study. Acta Psychiatr Scand 1995; 92: 220-4.
57. Neppe VM. Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. J Clin Psychiatry 1983; 44: 326-31.
58. Dose M, Apelt S, Emrich HM. Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Res 1987; 22: 303-10.
59. Nachshoni T, Levin Y, Levy A et al. A double-blind trial of carbamazepine in negative symptom schizophrenia. Biol Psychiatry 1994; 35: 22-6.